X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (13) 13
male (12) 12
aged (10) 10
female (9) 9
oncology (9) 9
index medicus (8) 8
middle aged (8) 8
adult (7) 7
survival (7) 7
cancer (6) 6
chemotherapy (6) 6
5-fluorouracil (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
gastroenterology & hepatology (5) 5
pancreatic neoplasms - pathology (5) 5
prognosis (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
care and treatment (4) 4
oxaliplatin (4) 4
treatment outcome (4) 4
adenocarcinoma - drug therapy (3) 3
deoxycytidine - administration & dosage (3) 3
deoxycytidine - analogs & derivatives (3) 3
disease-free survival (3) 3
folinic acid (3) 3
gemcitabine (3) 3
hematology, oncology and palliative medicine (3) 3
kaplan-meier estimate (3) 3
medical prognosis (3) 3
metastasis (3) 3
neoplasm metastasis (3) 3
pancreatic cancer (3) 3
pancreatic neoplasms - drug therapy (3) 3
pancreatic neoplasms - mortality (3) 3
plus gemcitabine (3) 3
prognostic-factors (3) 3
prospective studies (3) 3
second-line chemotherapy (3) 3
therapy (3) 3
tumors (3) 3
abridged index medicus (2) 2
adenocarcinoma (2) 2
adenocarcinoma - pathology (2) 2
advanced small bowel adenocarcinoma (2) 2
aged, 80 and over (2) 2
analysis (2) 2
camptothecin - analogs & derivatives (2) 2
cholangiocarcinoma (2) 2
cisplatin (2) 2
cisplatin - administration & dosage (2) 2
colorectal cancer (2) 2
combination (2) 2
dosage and administration (2) 2
drug therapy (2) 2
fluorouracil - adverse effects (2) 2
fluorouracil - therapeutic use (2) 2
folfiri (2) 2
folfiri.3 (2) 2
folfirinox (2) 2
folfox (2) 2
guidelines (2) 2
health aspects (2) 2
leucovorin (2) 2
leucovorin - adverse effects (2) 2
leucovorin - therapeutic use (2) 2
life sciences (2) 2
metastatic (2) 2
multivariate analysis (2) 2
neoplasms (2) 2
organoplatinum compounds - therapeutic use (2) 2
pancreatic adenocarcinoma (2) 2
patient outcomes (2) 2
peritoneal neoplasms - pathology (2) 2
phase-ii (2) 2
quality of life (2) 2
research (2) 2
second line (2) 2
surgery (2) 2
1st case-report (1) 1
2nd-line chemotherapy (1) 1
30-minute infusion (1) 1
[sdv.can]life sciences [q-bio]/cancer (1) 1
accuracy (1) 1
acute disease (1) 1
adenocarcinoma - mortality (1) 1
adenocarcinoma - psychology (1) 1
adenocarcinoma - secondary (1) 1
adenopathy (1) 1
adolescent (1) 1
advanced biliary tract cancer (1) 1
albumins - administration & dosage (1) 1
albumins - adverse effects (1) 1
antigens (1) 1
antimetabolites, antineoplastic - therapeutic use (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic combined chemotherapy protocols - administration & dosage (1) 1
appetite - physiology (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Quality of Life Research, ISSN 0962-9343, 7/2016, Volume 25, Issue 7, pp. 1713 - 1723
Journal Article
Journal Article
British Journal of Cancer, ISSN 0007-0920, 09/2015, Volume 113, Issue 7, pp. 989 - 995
Journal Article
European Journal of Cancer, ISSN 0959-8049, 04/2019, Volume 111, pp. 94 - 106
Journal Article
Cancer, ISSN 0008-543X, 09/2015, Volume 121, Issue 18, pp. 3290 - 3297
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2018, Volume 36, Issue 4_suppl, pp. 370 - 370
370 Background: Combination of nab-paclitaxel plus gemcitabine (N+G) has recently become a valid first-line treatment (1L) in metastatic pancreatic... 
Journal Article
Cancer, ISSN 0008-543X, 04/2011, Volume 117, Issue 7, pp. 1422 - 1428
BACKGROUND: Small bowel adenocarcinoma (SBA) is a rare tumor with poor prognosis. First‐line platinum‐based chemotherapy is active in patients with advanced... 
advanced small bowel adenocarcinoma | chemotherapy | second line | survival | FOLFIRI
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2014, Volume 50, Issue 18, pp. 3116 - 3124
Journal Article
Therapeutic Advances in Gastroenterology, ISSN 1756-283X, 9/2019, Volume 12, p. 175628481987866
Background: Folfirinox (FFX) and gemcitabine/nab-paclitaxel (GN) are both standard first-line treatments in patients with metastatic pancreatic cancer (mPC).... 
PLUS GEMCITABINE | pancreatic adenocarcinoma | metastatic | survival | nab-paclitaxel | Folfirinox | gemcitabine | GASTROENTEROLOGY & HEPATOLOGY
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2017, Volume 35, Issue 4_suppl, pp. 737 - 737
737 Background: A is approved in combination with FOLFIRI (A-FOLFIRI) for the treatment of mCRC patients (pts) previously treated with oxaliplatin. PULSAR... 
Journal Article
CANCER, ISSN 0008-543X, 04/2011, Volume 117, Issue 7, pp. 1422 - 1428
Journal Article
CANCERS, ISSN 2072-6694, 06/2019, Volume 11, Issue 7, p. 998
In patients with metastatic colorectal cancer (mCRC), RAS and BRAF mutations are currently determined by tumor sample analysis. Here, we report BRAF mutation... 
colorectal cancer | methylated biomarker | ONCOLOGY | accuracy | NGS | liver metastases | circulating tumor DNA | VEMURAFENIB | Life Sciences | Human health and pathology | Cancer
Journal Article
Journal Article